Arcus Biosciences Inc.

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Frequently asked questions
To buy Arcus Biosciences Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Arcus Biosciences Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Arcus Biosciences Inc. is RCUS:xnys. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Arcus Biosciences Inc. has its primary listing on New York Stock Exchange. You can trade Arcus Biosciences Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Arcus Biosciences Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Arcus Biosciences Inc. as part of a broader investment portfolio.